Dissecting the convergent and distinct roles of Gal-1 and Gal-3 in liver fibrosis using Gal-1, Gal-3, and Gal-1/Gal-3 double-knockout mice will benefit the development of anti-galectin drugs for liver fibrosis. This evidence concerns the gene LGALS1 and Hepatic fibrosis.